Screening the RFX6-DNA binding domain for potential genetic variants in patients with type 2 diabetes

Table 1 Demographic and clinical characteristics of diabetic patients and healthy controls

	Control group	Diabetic patients	P-value
Primary screening, (n = 98)
Male, n (%)	32 (65%)	24 (49%)	0.285
Age (mean ± SD)	50.1 ± 12.3	54.7 ± 10.7	0.149
Female, n (%)	17 (35%)	25 (51%)	0.217
Age (mean ± SD)	47.7 ± 15.5	56.2 ± 13.2	0.065
FBG (mg/dL)	97± 10	192± 94	< 0.001
HbA1c (%)	5.4± 0.4	8.2± 2.2	< 0.001
Screening the IVS6+31 C>T, (n = 283)
Male, n (%)	78 (55%)	59 (42%)	0.105
Age (mean ± SD)	48.9 ± 15.2	57.4 ± 11.3	0.001
Female, n (%)	64 (45%)	82 (58%)	0.136
Age (mean ± SD)	51.8 ± 15.2	57.1 ± 11.5	0.024
FBG (mg/dL)	98± 10.4	177± 80	< 0.001
HbA1c (%)	5.4± 0.5	7.8± 1.9	< 0.001

P-value is significant at ≤ 0.05. FBG: Fasting blood glucose; HbA1c: Glycosylated haemoglobin.